Showing posts with label Drugs. Show all posts
Showing posts with label Drugs. Show all posts

Monday, June 10, 2019

Soon, Air India may conduct random drug test on pilots, other crew members

Company News
In a first for Indian carriers, Air India is likely to start random drug tests on its pilots and cabin crew. Crew members who are found to have a drug abuse problem could be barred from operating flights till they completely give the same up for good. "There is no specific regulation monitoring drug testing… It is recommended that (AI’s) medical department is asked to devise a process for doing random testing for drugs as a safety initiative…” says a note titled “safety recommendations for psychoactive substances” sent by the airline’s ED and chief of flight safety, Harpreet A De Singh, to AI chairman and other top officials.
A senior airline official told TOI, Air India is planning to take this up as a “pioneering” effort to enhance flight safety in India.
According to DGCA's 'General Safety Conditions' circular, the clause titled, "prohibition on consumption of intoxicating and psychoactive substances", states, "no pilot, commander, navigator, engineer, cabin crew or other operating members of the crew shall have taken or used any alcoholic drink, sedative, narcotic or stimulant drug or preparation within twelve hours of the commencement of the flight or take or use any such preparation in the course of the flight, and no such person shall be in a state of intoxication or have detectable blood alcohol whatsoever in his breath, urine or blood alcohol analysis."

 Pre and post-flight breath analyser (BA) tests are conducted by all airlines. A pilot is grounded for three months, three years and forever after failing pre-flight BA test for the first, second and third time, respectively. Those failing the breath analyser tests in post-flight checks get a year added to these groundings.

Friday, March 22, 2019

Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market

Companies News

* The growth of the Indian Pharma market has come down from 13.5 per cent in FY15 to 10 per cent YoY in FY18

* Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs

* Growing awareness about cheaper alternatives to branded generics and more channels providing access to them has started to impact volume growth for branded generics

* The Government's push towards Jan Aushadhi stores has started to impact volumes of branded generics

* The Pradhan Mantri Jan Aushadhi scheme aims to provide quality drugs at almost 50-90% discount to their branded counterparts

* Jan Aushadhi stores cover a list of 800 plus drugs, both chronic and acute, across therapies like anti-cancer, anti-infective, reproductive and gastro intestinal medicines

* There are 5000+ Jan Aushadhi stores now and another 2500 to be opened by 2020

* Edelweiss noted revenue of the Jan Aushadhi scheme is expected to double YoY in FY19. Revenue of Rs 300 crore expected in FY19

* Can potentially disrupt 1% of IPM


 * Edelweiss noted that the Rs 120 crore sales of BPPI in FY18 corresponds to Rs 600 crore of branded products.